Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00452140
Status:
TERMINATED
Last Update Posted:
2009-05-19
First Post:
2007-03-26
Brief Title:
Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment
Sponsor:
Neovii Biotech
Organization:
Neovii Biotech
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Metastatic Breast Cancer |
| Advanced Breast Cancer |
Keywords:
| Name | View |
|---|---|
| Her-2neu | View |
| Breast Cancer | View |
| investigational drug | View |
| drug therapy | View |
| Antineoplastic Protocols | View |
| Immunotherapy | View |
| Metastatic breast cancer | View |
| Advanced breast cancer | View |
| Stage III to IV breast cancer | View |
| Hormonal therapy refractory | View |
| Failure of hormonal therapy | View |
| Her-2neu expressing breast cancer | View |